1,2-二氢-6,7-二甲氧基萘 | 35491-96-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 1,2-二氢-6,7-二甲氧基萘
• 英文名称: 6,7-dimethoxy-1,2-dihydronaphthalene
• 英文别名: 1,2-dihydro-6,7-dimethoxynaphthalene；6,7-Dimethoxy-3,4-dihydronaphthalene
• CAS: 35491-96-4
• 化学式: C₁₂H₁₄O₂
• 分子量: 190.242
• InChiKey: YZSSUCIPIBBMKJ-UHFFFAOYSA-N

物化性质

• 熔点：
  35.5-36 °C
• 沸点：
  119-121 °C(Press: 0.3 Torr)
• 密度：
  1.071±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,2-二氢-6,7-二甲氧基萘 在 间氯过氧苯甲酸 作用下， 以75%的产率得到5,6-Dimethoxy-1a,2,3,7b-tetrahydronaphtho[1,2-b]oxirene
  参考文献：
  名称：

  [EN] DOPAMINE RECEPTOR LIGANDS WITH ENHANCED DURATION OF ACTION
  [FR] LIGANDS DE RÉCEPTEUR DE DOPAMINE À DURÉE D'ACTION PROLONGÉE

  摘要：

  公开号：

  WO2010017093A3
• 作为产物：
  描述：

  4-(3,4-二甲氧苯基)丁酸 在 lithium aluminium tetrahydride 、 PPA 、 Polyphosphoric acid (PPA) 、 magnesium sulfate 作用下， 以 四氢呋喃 、 苯 为溶剂， 反应 5.25h， 生成 1,2-二氢-6,7-二甲氧基萘
  参考文献：
  名称：

  Dopaminergic agonists: comparative actions of amine and sulfonium analogs of dopamine

  摘要：

  We have investigated the possibility that structural modifications of the sulfonium analogue of dopamine (4) would produce the same pattern of biological activity as structural modifications of dopamine. A series of methyl- tetralinyl -, and naphthalenylsulfonium analogues 5-7 were prepared and tested for their ability to inhibit the potassium-evoked release of [3H]acetylcholine from striatal slices. All compounds were tested under normal conditions and after depletion of dopamine stores with reserpine and alpha-methyl-p-tyrosine. The amine and sulfonium analogues 2-6 all showed direct agonist activity. The sulfonium analogue 7 produced, predominantly, indirect activity. In contrast to the amine analogues, chemical modifications of the sulfonium compounds produced little change in their dopamine agonist activity.

  DOI：

  10.1021/jm00371a021

文献信息

• Substituted dibenzo[ c,h ]cinnolines: topoisomerase I-targeting anticancer agents
  作者：Younong Yu、Sudhir K Singh、Angela Liu、Tsai-Kun Li、Leroy F Liu、Edmond J LaVoie

  DOI：10.1016/s0968-0896(02)00604-1

  日期：2003.4

  9-methylenedioxybenzo[i]phenanthridine is one of the more potent benzo[i]phenanthridine derivatives in regard to topoisomerase I-targeting activity and cytotoxicity. The structure-activity relationship observed with these substituted dibenzo[c,h]cinnolines parallels that observed for benzo[i]phenanthridine derivatives. Compared to similarly substituted benzo[i]phenanthridines, the dibenzo[c,h]cinnoline analogues

  合成了几种取代的二苯并[c，h]肉桂啉，并评估了其靶向拓扑异构酶I的潜力以及相对的细胞毒性活性。选择的苯并[i]菲啶能够稳定由拓扑异构酶I和DNA形成的可裂解复合物。开始这项研究以检查本质上是苯并[i]菲啶的氮杂类似物的二苯并[c，h] cinnolines是否具有相似的药理特性。就靶向拓扑异构酶I的活性和细胞毒性而言，2，3-二甲氧基-8，9-亚甲基二氧基苯并[i]菲啶是更有效的苯并[i]菲啶衍生物之一。用这些取代的二苯并[c，h] cinnolines观察到的结构活性关系与苯并[i]菲啶衍生物观察到的相似。与类似取代的苯并[i]菲啶相比，二苯并[c，h] cinnoline类似物表现出更强的拓扑异构酶I靶向活性和细胞毒性。在评估2,3-二甲氧基-8,9-亚甲基二氧基二苯并[c，h] cinnoline和2,3-二甲氧基-8,9-亚甲基二氧基苯并[i]菲啶在人淋巴母细胞瘤中的细胞毒性时获
• Catalytic Enantioselective Arylboration of Alkenylarenes
  作者：Kaitlyn M. Logan、M. Kevin Brown

  DOI：10.1002/anie.201609844

  日期：2017.1.16

  A method for the catalytic enantioselective arylboration of alkenylarenes is disclosed. The reaction leads to the formation of 1,1‐diarylalkanes that also incorporate an additional pinacol boronic ester which can be easily transformed to a variety of groups. The products are formed with excellent diastereoselectivities and enantioselectivities.

  公开了用于烯基芳烃的催化对映选择性芳基硼化的方法。该反应导致形成1,1-二芳基烷烃，该烷烃还掺入了另外的频哪醇硼酸酯，可以轻松转化为各种基团。形成的产物具有优异的非对映选择性和对映选择性。
• Tetracyclic compounds as dopamine agonists
  申请人：Abbott Laboratories

  公开号：US05597832A1

  公开（公告）日：1997-01-28

  A tetracyclic compound of the formula: ##STR1## wherein A and the atoms to which it is attached and the optional double bond represent a mono- or di-heterocyclic ring selected from: ##STR2## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and X are specifically defined, which compounds are useful in the treatment of dopamine-related neurological, psychological and cardiovascular disorders as well as in the treatment of substance abuse and other addictive behavior disorders, cognitive impairment and attention deficit disorder.

  一种四环化合物的化学式：##STR1## 其中A及其连接的原子和可选的双键代表从中选择的单环或双环杂环环，该环选自：##STR2## 其中R.sup.1、R.sup.2、R.sup.3、R.sup.4和X具体定义，这些化合物在治疗与多巴胺相关的神经、心理和心血管疾病以及物质滥用和其他成瘾行为障碍、认知损害和注意力缺陷障碍方面具有用处。
• Synthesis and dopaminergic activity of 2-substituted octahydrobenzo[f]quinolines
  作者：J. Cymerman Craig、Steven M. Torkelson、Paul R. Findell、Richard I. Weiner

  DOI：10.1021/jm00125a007

  日期：1989.5

  A series of 2-substituted octahydrobenzo[f]quinolines has been synthesized and assayed for dopamine agonist activity. Only the compounds corresponding to the beta-rotameric conformation of dopamine showed biphasic activity in competition binding studies with the radioligand [3H]spiroperidol. These findings suggest that the congeners possessing the beta-rotamer conformation show receptor-binding characteristics

  已经合成了一系列2-取代的八氢苯并[f]喹啉，并对其多巴胺激动剂活性进行了测定。在与放射性配体[3H]螺哌啶醇的竞争结合研究中，仅对应于多巴胺β-旋转异构体构象的化合物显示出两相活性。这些发现表明，与相应的α-旋转异构体相比，具有β-旋转异构体构象的同源物显示出与麦角灵类似的受体结合特性。
• Substituted Hexahydrobenzo[<i>f</i>]thieno[<i>c</i>]quinolines as Dopamine D1-Selective Agonists:  Synthesis and Biological Evaluation <i>in Vitro</i> and <i>in Vivo</i>
  作者：Michael R. Michaelides、Yufeng Hong、Stanley DiDomenico、Erol K. Bayburt、Karen E. Asin、Donald R. Britton、Chun Wel Lin、Kazumi Shiosaki

  DOI：10.1021/jm970038v

  日期：1997.5.1

  A series of substituted 9,10-dihydroxyhexahydrobenzo[f]thieno[c]quinolines (TB[f]Q), varying with respect to the position of the thiophene relative to the benzo[f]quinoline core and the nature and position of the substituent on the thiophene, were prepared and evaluated for their affinity and selectivity for the dopamine D1-like receptor. The thieno[3,2-c]B[f]Q regioisomers bearing a small alky1 (C1-C3)

  一系列取代的9,10-二羟基六氢苯并[f]噻吩并[c]喹啉（TB [f] Q），相对于噻吩相对于苯并[f]喹啉核心的位置以及其性质和位置而有所不同制备噻吩上的取代基并评估它们对多巴胺D1样受体的亲和力和选择性。在2位带有一个小的烷基1（C1-C3）取代基的硫代[3,2-c] B [f] Q区域异构体是有效的（Ki <20 nM）和选择性的（D2 / D1> 50）D1激动剂达到完全的激动剂活性（IA> 85％）。化合物被拆分，发现在与D1受体的相互作用中表现出高水平的对映体特异性。在帕金森氏病的6-OHDA啮齿动物模型中对选定的化合物进行了体内测试，以及它们在小鼠中产生癫痫样活动的责任。